RS
FATE icon

R Squared’s Fate Therapeutics FATE Stock Holding History

R Squared’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4K Sell
13,122
-5,402
-29% -$10K 0.02% 466
2026
Q1 		$22.2K Buy
18,524
+8,066
+77% +$9.82K 0.01% 462
2025
Q4 		$10.3K Sell
10,458
-7,471
-42% -$8.97K ﹤0.01% 509
2025
Q3 		$22.6K Buy
+17,929
New +$19.3K 0.01% 525
2025
Q1 		– Sell
-600
Closed -$990 – 686
2024
Q4 		$990 Buy
+600
New +$1.51K ﹤0.01% 1514

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

R Squared's FATE Position: Q2 2026 in Review

R Squared reduced its Fate Therapeutics (FATE) stake by 29% in Q2 2026, selling an estimated $10K and leaving 13,122 shares worth $35.4K. The position accounts for 0.02% of the portfolio, ranked #466.

R Squared first reported a position in FATE in Q4 2024 and has held it in 5 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • R Squared held 13,122 shares of Fate Therapeutics worth $35.4K as of Q2 2026.
  • R Squared sold 5,402 Fate Therapeutics shares in Q2 2026, an estimated $10K.
  • Fate Therapeutics made up 0.02% of R Squared's portfolio in Q2 2026, its #466 holding.
  • R Squared first reported a position in Fate Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.